Lineage Cell Q1 Loss Widens to $0.03, Revenue Misses Estimates
Lineage Cell reported a Q1 adjusted loss of $0.03 per share, exceeding the $0.02 consensus estimate and up from a $0.02 per-share loss in Q1 2025. The company also missed revenue estimates, highlighting persistent top-line weakness.
1. Q1 Financial Results
Lineage Cell delivered a first-quarter GAAP loss of $0.03 per share, compared with analyst expectations of a $0.02 loss and a $0.02 loss in Q1 2025. The wider loss reflects elevated R&D and commercialization expenses as the company advances its cell therapy pipeline.
2. Revenue Shortfall and Outlook
The company’s revenue fell short of consensus estimates, underscoring ongoing challenges in scaling product sales and partnership milestones. This performance may pressure cash reserves, prompting management to consider guidance adjustments or additional financing to support clinical programs.